Cell line · CVCL_2213
Papers66
1 to 20 of 66
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting GPX4 and FSP1 to exploit ferroptotic vulnerability in Ewing sarcoma. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Drug Screening of Sarcoma Cells: Finding Shared Sensitivities. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| FET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners. | Cell Mol Biol Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40376089 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 helicase impacts on splicing decisions by modulating U2 snRNP recruitment in Ewing sarcoma cells. | Nucleic Acids Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. | Genome Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| USP1 Expression Driven by EWS::FLI1 Transcription Factor Stabilizes Survivin and Mitigates Replication Stress in Ewing Sarcoma. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2213/papers